^
Association details:
| Biomarker: | CMTM4 expression + PD-L1 expression |
|---|---|
| Cancer: | Gastric Adenocarcinoma |
| Drug Class: | Immunotherapy |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Co-Expression with Membrane CMTM6/4 on Tumor Epithelium Enhances the Prediction Value of PD-L1 on Anti-PD-1/L1 Therapeutic Efficacy in Gastric Adenocarcinoma
Published date:
10/15/2021
Excerpt:
Collectively, these data demonstrated that pattern 1 with membrane expression of CMTM6+PD-L1+ and/or CMTM4+PD-L1+ on the surface of tumor epithelium is associated with better response to anti-PD-1/L1 therapy. The membrane co-expression of CMTM6/4 with PD-L1 on the tumor epithelial cells may thus be a promising criterium for precision therapeutic patient stratification....In summary, the co-expression of CMTM6/4 with PD-L1 on the membrane of gastric cancer cells predicts poor prognosis as well as better short-term efficacy of immunotherapy with anti-PD-1/L1 antibodies.
DOI:
https://doi.org/10.3390/cancers13205175
